Overall, there is clear evidence that targeting ATG4B can provide a benefit in cancer, and there is particularly good evidence for breast cancer, lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. This evidence concerns the gene ATG4B and lung carcinoma.